Drug Profile
TDENV PIV
Alternative Names: Tetravalent purified inactivated dengue vaccine - GlaxoSmithKline/Walter Reed Army Institute of ResearchLatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Walter Reed Army Institute of Research
- Developer GSK; United States Army Medical Research and Materiel Command; Walter Reed Army Institute of Research
- Class Dengue vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Dengue
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Dengue(Prevention) in Puerto Rico (IM, Injection)
- 11 May 2017 U.S. Army Medical Research and Materiel Command plans a phase I trial for Dengue (Prevention) in USA (NCT03141138)
- 11 May 2017 Phase I development in Dengue (Prevention) in Puerto Rico (NCT01702857)